Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Peñalver, FJ ; Marquez, JA ; Duran, S ; Giraldo, P ; Martin, A ; Montalban, C ; Sancho, JM ; Ramirez, MJ ; Terol, MJ ; Capote, FJ ; Gutierrez, A ; Sanchez, B ; Lopez, A ; Salar, A ; Rodriguez-Caravaca, G ; Canales, M ; Caballero, MD ; Lopez, JLB ; Carbonell, F ; Bordas, SF ; Lopez, PF ; Persona, EP ; Guillermo, AL ; Martin, RH ; Mayans, JR ; Palomera, L (Universidad de Zaragoza) ; Ceballos, EP ; Hernandez, JAQ ; Grau, RR ; de la Cruz, F ; Salinas, AS
Resumen: Background Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods This phase II trial evaluated the efficacy and safety of response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) in follicular lymphoma patients who relapsed after or were refractory to first-line immunochemotherapy. Sixty patients received three treatment cycles, and depending on their response received an additional one (complete/unconfirmed complete response) or three (partial response) cycles. Patients who responded to induction received rituximab maintenance therapy for 2 years. Results Thirty-three (55%) and 42 (70%) patients achieved complete/unconfirmed complete response after three cycles and on completing induction therapy (4-6 cycles), respectively (final overall response rate, 88.3%). Median progression-free survival was 56.4 months (median follow-up, 28.3 months; 95% CI, 15.6-51.2). Overall survival was not reached. Progression-free survival did not differ between patients who received four vs six cycles (P = .6665), nor between patients who did/did not receive rituximab maintenance after first-line therapy (P = .5790). Median progression-free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6-N/A) and was longer in patients who had shown progression of disease after 24 months of first-line therapy (median, 56.4 months; 95% CI, 19.8-56.4) than in those who showed early progression (median, 42.31 months; 95% CI, 24.41-NA) (P = .4258). Thirty-six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively). Conclusions This response-adapted treatment with RBMD followed by rituximab maintenance is an effective and well-tolerated salvage treatment for relapsed/refractory follicular lymphoma following first-line immunochemotherapy.
Idioma: Inglés
DOI: 10.1002/cam4.2555
Año: 2019
Publicado en: Cancer medicine 8, 16 (2019), 6955-6966
ISSN: 2045-7634
Factor impacto JCR: 3.491 (2019)
Categ. JCR: ONCOLOGY rank: 111 / 244 = 0.455 (2019) - Q2 - T2
Factor impacto SCIMAGO: 1.315 - Radiology, Nuclear Medicine and Imaging (Q1) - Cancer Research (Q2) - Oncology (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2023-09-13-10:46:52)
Visitas y descargas
Idioma: Inglés
DOI: 10.1002/cam4.2555
Año: 2019
Publicado en: Cancer medicine 8, 16 (2019), 6955-6966
ISSN: 2045-7634
Factor impacto JCR: 3.491 (2019)
Categ. JCR: ONCOLOGY rank: 111 / 244 = 0.455 (2019) - Q2 - T2
Factor impacto SCIMAGO: 1.315 - Radiology, Nuclear Medicine and Imaging (Q1) - Cancer Research (Q2) - Oncology (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2023-09-13-10:46:52)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2020-01-03, last modified 2023-09-14